To make disease-modifying first-in-class immuno-oncology treatments available to patients suffering from devastating conditions such as cancer
Medibiofarma focused internal resources on areas where lies the experience of the management team:
The remaining activities needed for the full compound characterization and the nomination of a development candidate, such as in vivo pharmacology and toxicology and IND-enabling studies are carried out through partnerships with several companies (CROs), Research Centers and Universities.
Medibiofarma has just closed a financing round of 1.2 million euros, supported by the founder’s and other VC partners with proven experience in the field of health and technology, such as Sodena...
Navarra – July 2021– Medibiofarma S.L., a clinical-stage biotechnology company developing, as part of its portfolio of projects, a new disease-modifying therapy for the treatment of...
